Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. AB Science
EIR
•AB Science•September 26, 2014

AB Science – FDA EIR, Sep 26, 2014

Record Details

An FDA inspection of AB Science, Paris, France, was conducted from September 22-26, 2014, as a for-cause follow-up under CDER Compliance Program 7348.810. The inspection, with participation from the French regulatory authority (ANSM), revealed significant deficiencies in the company's oversight and monitoring of clinical investigations, particularly concerning its investigational drug, (b)(4). Key violations included the failure to properly monitor clinical investigations, provide investigators with necessary information, and ensure studies adhered to general plans and protocols. Monitors consistently failed to deliver adequate investigator training, submit timely reports, and retrieve local clinical laboratory results. Several principal investigators were absent during critical site initiation and interim monitoring visits, and AB Science lacked clear procedures for addressing investigator non-compliance. A notable lapse involved an investigator's failure to modify a subject's drug dose despite Grade 2 renal failure, violating protocol stopping rules, which the sponsor did not address. The FDA issued a Form 483 to CEO Mr. Alain Moussy, who committed to implementing corrective actions. These included plans to enhance monitoring programs, establish a robust Quality Assurance System, set stringent reporting timelines for Clinical Research Associates, and allocate increased resources for quality control, potentially engaging external auditors. This inspection built upon previous findings of recordkeeping deficiencies, inaccurate reporting, and inadequate safety information disclosures.

Company
AB Science
Inspection date
September 26, 2014
Product type
Drugs
Office
Division of Scientific Investigations
People
  • Ni A. Khin (issuing_officer)
  • Alain Moussy (recipient)
  • Michelle L. Safarik (investigator)
  • Albert Ahn (company_representative)
  • Barbara D. Wright (investigator)
View Company Profile

ID · dd3d399c-2682-43b1-ae86-f78cc2801106

Violation Codes5
21 CFR 312.5021 CFR 820.10021 CFR 312.5621 CFR 312.5521 CFR 312

Full citation text and observation details available on the Dashboard.

Other documents for AB Science
  • WARNING_LETTER - 2014-09-26September 26, 2014
  • WARNING_LETTER

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore AB Science
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.